Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation.
Disparity for the minor histocompatibility antigen HA-1 between patient and donor has been associated with an increased risk of acute graft-versus-host disease (GvHD) after allogeneic human leucocyte antigen (HLA)-identical sibling donor stem cell transplantation (SCT). However, no data concerning the impact of such disparity on chronic GvHD, relapse or overall survival are available. A retrospective multicentre study was performed on 215 HLA-A2-positive patients who received an HLA-identical sibling SCT, in order to determine the differences in acute and chronic GvHD incidence on the basis of the presence or absence of the HA-1 antigen mismatch. Disease-free survival and overall survival were also analysed. We detected 34 patient-donor pairs mismatched for HA-1 antigen (15.8%). Grades II-IV acute GvHD occurred in 51.6% of the HA-1-mismatched pairs compared with 37.1% of the non-mismatched. The multivariate logistic regression model showed statistical significance (P: 0.035, OR: 2.96, 95% CI: 1.07-8.14). No differences were observed between the two groups for grades III-IV acute GvHD, chronic GvHD, disease-free survival or overall survival. These results confirmed the association between HA-1 mismatch and risk of mild acute GvHD, but HA-1 mismatch was not associated with an increased incidence of chronic GvHD and did not affect relapse or overall survival.
Gallardo
D
D
Alloreactivity Unit of the Institut Català d'Oncologia, Hospital Durán i reynals, Avda. Gran via s/n, km 2.7, 08907 L'Hospitalet, Barcelona, Spain. 27532dgg@comb.es
Aróstegui
J I
JI
Balas
A
A
Torres
A
A
Caballero
D
D
Carreras
E
E
Brunet
S
S
Jiménez
A
A
Mataix
R
R
Serrano
D
D
Vallejo
C
C
Sanz
G
G
Solano
C
C
Rodríguez-Luaces
M
M
Marín
J
J
Baro
J
J
Sanz
C
C
Román
J
J
González
M
M
Martorell
J
J
Sierra
J
J
Martín
C
C
de la Cámara
R
R
Grañena
A
A
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000276:immunology / Q000628:therapy; D016009:Chi-Square Distribution; D002908:Chronic Disease; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D016015:Logistic Models; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015778:Minor Histocompatibility Antigens / Q000276:immunology*; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy; D009190:Myelodysplastic Syndromes / Q000276:immunology / Q000628:therapy; D009842:Oligopeptides; D015996:Survival Rate; D014181:Transplantation Immunology
C110615:HA-1 antigen; D015778:Minor Histocompatibility Antigens; D009842:Oligopeptides